| Naslov: | In vitro evaluation of electrochemotherapy combined with sotorasib in pancreatic carcinoma cell lines harboring distinct kras mutations |
|---|
| Avtorji: | ID Jesenko, Tanja (Avtor)
ID Omerzel, Maša (Avtor)
ID Živič, Tina (Avtor)
ID Serša, Gregor (Avtor)
ID Čemažar, Maja (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://pmc.ncbi.nlm.nih.gov/articles/PMC12346384/
 PDF - Predstavitvena datoteka, prenos (743,73 KB)
MD5: 30499687CEC5BE528FAC17BAADEE9044
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Pancreatic cancer is among the deadliest malignancies, with limited treatment options and poor prognosis. Novel strategies are therefore urgently needed. Sotorasib, a KRAS G12C-specific inhibitor, offers targeted treatment for a small subset of patients with this mutation. Electrochemotherapy (ECT), which enhances the cytotoxicity of chemotherapeutic agents through electroporation-induced membrane permeabilization, has shown promise in various tumor types, including deep-seated malignancies such as pancreatic cancer. Combining ECT with sotorasib may potentiate antitumor effects in KRAS G12C-mutated pancreatic cancer; however, preclinical data on such combinations are lacking. This proof-of-concept study evaluated the cytotoxic effects of ECT using bleomycin (BLM) or cisplatin (CDDP) in combination with sotorasib in KRAS G12C-mutated MIA PaCa-2 and KRAS G12D-mutated PANC-1 pancreatic cancer cell lines. ECT alone significantly reduced cell viability, particularly in MIA PaCa-2 cells, where electric pulses induced approximately 75% cell death. Combining ECT with sotorasib resulted in an additive effect on KRAS G12C-mutated MIA PaCa-2 cells, though no synergy was observed, likely due to the high intrinsic sensitivity to electric pulses. These results support the potential of combining physical and molecular therapies in a subset of pancreatic cancer patients and lay the groundwork for further in vivo studies to optimize treatment parameters and explore clinical translatability. |
|---|
| Ključne besede: | bleomycin, cisplatin, electrochemotherapy, pancreatic cancer |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 30.05.2025 |
|---|
| Datum sprejetja članka: | 22.07.2025 |
|---|
| Datum objave: | 24.07.2025 |
|---|
| Kraj izida: | Basel |
|---|
| Založnik: | MDPI, Basel, Switzerland |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 7165-1-7165-10 |
|---|
| Številčenje: | Vol. 26, no. 15 |
|---|
| Izvor: | Basel, Switzerland |
|---|
| PID: | 20.500.12556/DiRROS-24008  |
|---|
| UDK: | 602 |
|---|
| ISSN pri članku: | 1422-0067 |
|---|
| DOI: | 10.3390/ijms26157165 |
|---|
| COBISS.SI-ID: | 245948931 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 19. 8. 2025;
|
|---|
| Datum objave v DiRROS: | 26.11.2025 |
|---|
| Število ogledov: | 92 |
|---|
| Število prenosov: | 44 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
